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ABSTRACT
Background: It is unknown whether prenatal lipid-based nutrient supplements (LNSs) affect blood pressure (BP).
Associations between hypertension and birth outcomes using recently updated BP cutoffs are undetermined.
Objectives: We aimed to assess the impact of LNSs on maternal hypertension and associations between hypertension
and birth outcomes.
Methods: Pregnant Ghanaian women at ≤20 weeks of gestation (n = 1320) were randomly assigned to receive daily
1) iron and folic acid (IFA), 2) multiple micronutrients (MMN), or 3) LNSs until delivery. BP was measured at enrollment
and 36 weeks of gestation. We analyzed the effect of LNSs on BP using ANOVA and associations between hypertension
[systolic BP (SBP) ≥130 mm Hg or diastolic BP (DBP) ≥80 mm Hg] and birth outcomes by linear and logistic regressions.
Results: Mean ± SD SBP and DBP were 110 ± 11 and 63 ± 8 mm Hg at 36 weeks of gestation and did not differ by
supplementation group (SBP, P > 0.05; DBP, P > 0.05). At enrollment, higher DBP was associated with lower birth weight
and shorter gestation; women with high DBP had greater risk of low birth weight (LBW) [risk ratio (RR): 2.58; 95% CI:
1.09, 6.08] and preterm birth (PTB) (RR: 3.30; 95% CI: 1.47, 7.40). At 36 weeks of gestation, higher SBP was associated
with lower birth weight, length, and head circumference and shorter gestation; higher DBP was associated with lower
birth weight and length; and women with high DBP had greater risk of LBW (RR: 3.39; 95% CI: 1.32, 8.69). Neither high
SBP nor hypertension were associated with birth outcomes at either time point.
Conclusions: Daily provision of LNSs does not affect maternal hypertension, compared with IFA and MMN. Higher
SBP and DBP are associated with a shorter gestation and smaller birth size; however, only high DBP is associated
with LBW and PTB. The new BP cutoffs may help identify pregnancies at risk of adverse birth outcomes. This trial was
registered at clinicaltrials.gov as NCT00970866. J Nutr 2021;00:1–9.
Keywords: birth outcomes, Ghana, maternal blood pressure, prenatal supplements, maternal hypertension, low
birth weight, preterm birth
Introduction
Hypertension is currently defined as a systolic blood pressure
(SBP) ≥130 mm Hg or diastolic blood pressure (DBP)
≥80 mm Hg (1). The definition was recently updated by the
American Heart Association, which previously designated an
SBP ≥140 mm Hg or DBP ≥90 mm Hg as hypertension,
based on the increased risk of cardiovascular disease in adult
populations in the United States (1). Based on the previous
hypertension cutoffs, >20% of pregnancies in Ghana are
affected by hypertension (2), compared with ∼10% worldwide
(3). The disparity may be related to lack of access to adequate
health care, a delay in seeking health care, or delayed response
to maternal health status at the health care facilities (4).
During a typical pregnancy, blood pressure (BP) decreases
from early (<15 weeks of gestation) to mid-pregnancy (22–
24 weeks of gestation), increases in late pregnancy (36 weeks
of gestation), and then returns to prepregnancy levels by
C© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition. This is an Open Access article distributed under the
terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction
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delivery (4, 5). However, during pregnancy BP may not change
as expected, and hypertension may develop. Compared with
antihypertensive medication, which may increase the risk of
pregnancy complications (6, 7), nutritional supplements may
be an effective and preferred strategy to decrease the risk of
maternal hypertension.
Increased dietary intake of essential fatty acids (EFAs)
has been shown to decrease the risk of hypertension in
nonpregnant populations (8). Although the exact mechanisms
between hypertension and dietary EFAs are unclear, EFAs
have been associated with increased anti-inflammatory effects,
antioxidation, endothelial vasodilation, vascular compliance,
and inhibition of the renin–angiotensin–aldosterone system
(8). There is emerging evidence that lipids, specifically EFAs,
may play a role in decreasing placental dysfunction and
inflammation, and supporting increased fetal growth (9, 10).
However, EFAs have been associated with reduced risk of
hypertension and inflammatory markers during pregnancy only
in animal studies. Larger intervention studies have not shown
significant associations between EFA supplementation or intake
and maternal hypertension (11). There is also no evidence
from African populations regarding the effects of nutrient
supplements that include EFAs on maternal hypertension,
although the prevalence of hypertensive disorders of pregnancy
in Africa may be as high as 10%–25% (12).
It is unclear whether the new definition of hypertension,
which uses a lower threshold, is appropriate for predicting
pregnancies at risk of adverse outcomes. High BP during
pregnancy, as defined by the previous cutoffs, has been
associated with an increased risk of low birth weight (LBW)
(13), small for gestational age (SGA), and preterm birth (PTB)
(13, 14). It is important to minimize the risk of adverse
birth outcomes because they have both short- and long-term
consequences on newborn health. These consequences include
infections (15), breathing difficulties (16), and increased risk of
diabetes and obesity (17) and intellectual and developmental
disabilities (18).
Ghana is a low-middle-income country located in Western
Africa, with staple foods that include maize, cassava, rice, fish,
and leafy vegetables. The country is currently experiencing
a nutrition transition to more energy-dense, “Western” diets
and corresponding increases in overweight and obesity. Several
micronutrient deficiencies, including iron, folate, and vitamin
A, are common in Ghana, and especially among lower-income
households (19). Dietary intake of calcium was also reported
to be low among women of childbearing age in the Manya
Krobo District in the Eastern Region of Ghana (20). Calcium
supplementation daily has been associated with a decreased
risk of maternal hypertension, although evidence suggests that a
protective effect is evident only among women with low dietary
calcium intake (21). Given the high prevalence of hypertension
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in Ghana, it is important to identify effective strategies to
decrease maternal BP and prevent associated adverse birth
outcomes (22).
Our objectives were to 1) evaluate the impact of prenatal
lipid-based nutrient supplements (LNSs) on maternal BP; and
2) assess the association between maternal BP during early and
late pregnancy and birth outcomes using the new BP cutoffs. We
hypothesized that women receiving LNSs would have a lower
mean SBP and DBP than those receiving iron and folic acid (IFA)
or multiple micronutrients (MMN) at 36 weeks of gestation. We
also hypothesized that hypertension during pregnancy would be
associated with a smaller newborn birth size and lower duration
of gestation than in women with normal BP.
Methods
Study design
We report on a secondary data analysis of 1 of the randomized
controlled trials in the International Lipid-Based Nutrient Supplements
(iLiNS) Project, the iLiNS-DYAD trial in Ghana (23). A total of 1320
women were recruited from the Yilo and Manya Krobo districts of
Ghana, randomly assigned to 1 of 3 groups, and received 1) IFA
supplements that contained 60 mg Fe and 400 μg folic acid, 2) MMN
that contained 1–2 RDAs of 18 vitamins and minerals, or 3) small-
quantity LNSs that contained the same micronutrients as the MMN as
well as calcium, phosphorus, potassium, magnesium, EFAs, and other
macronutrients from enrollment until delivery. Table 1 provides the
composition of the supplements, as well as a comparison to current
RDAs during pregnancy (24–29). The main objective of this trial was
to determine the effects of nutrient supplements for the mother during
pregnancy and the first 6 mo postpartum, and for the child from 6–
18 mo, on child growth through 18 mo of age. For this secondary
analysis, data collected from enrollment, with a mean gestational age
of 16 wk, through birth were used (23).
The small-quantity (20 g/d) LNS provided to women in this trial
was a paste designed to be mixed with local foods to increase the
nutrient and energy content of diets during pregnancy and lactation
(30). Nutriset SAS produced the LNS in 20-g sachets and DSM South
Africa produced the capsules of the IFA and MMN supplements. A more
detailed description of the study population and methods has previously
been published (23). The iLiNS-DYAD study protocol was approved by
the institutional review boards at the University of California, Davis; the
Noguchi Memorial Institute for Medical Research, University of Ghana;
and the Ghana Health Service.
Eligibility for this study was specific to women attending 4 prenatal
clinics in the Yilo and Manya Krobo districts of Ghana between
December 2009 and December 2011, who were ≥18 y old, and at
≤20 weeks of gestation as determined by ultrasound. Reasons for
exclusion were a test result that was HIV positive, residence > 20 km
outside of the study area, history of peanut or milk allergies, severe
illness, or the intention to move out of the study area within 2 y.
A block-randomization scheme was designed and implemented by
a study statistician and has been detailed previously (23). Each woman
was randomly assigned into the IFA, MMN, or LNS group. To ensure
blinding, an independent party from the research team color-coded
the supplement capsules for the IFA and MMN groups that were
then provided to blinded investigators, fieldworkers, and participants.
Because the LNS was not a capsule, fieldworkers and participants could
not be blinded from distinguishing between the LNS and IFA or MMN.
Anthropometrists were not aware of the group allocations, and data
analysts were blinded until the completion of preliminary analyses.
Procedures
At enrollment and 36 weeks of gestation, trained fieldworkers
interviewed participants to record sociodemographic characteristics.
A study nurse measured height (Seca 217), weight (Seca 874),
and duplicate BP measurements on either arm using automated
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TABLE 1 Composition of supplements provided to pregnant women in the International
Lipid-Based Nutrient Supplements-DYAD trial in Ghana1
Nutrient RDA (pregnancy) IFA MMN LNS
Ration, g/d 1 tablet 20
Total energy, kcal 0 118
Protein, g 0 2.6
Fat, g 0 10
Linoleic acid, g 13∗ 0 4.59
α-Linolenic acid, g 1.4∗ 0 0.59
Vitamin A (retinyl acetate), μg RE 770 800 800
Vitamin C (L-ascorbic acid), mg 85 100 100
Thiamin (thiamin hydrochloride), mg 1.4 2.8 2.8
Riboflavin, mg 1.4 2.8 2.8
Niacin (niacinamide), mg 18 36 36
Folic acid (pteroyl monoglutamic acid), μg 600 400 400 400
Pantothenic acid (calcium pantothenate), mg 6∗ 7 7
Vitamin B-6 (pyridoxine hydrochloride), mg 1.9 3.8 3.8
Vitamin B-12 (cyanocobalamin 0.1%), μg 2.6 5.2 5.2
Vitamin D (cholecalciferol), IU 600 400 400
Vitamin E (DL-α-tocopherol acetate), mg 15 20 20
Vitamin K (phylloquinone 5%), μg 90∗ 45 45
Iron (ferrous sulfate), mg 27 60 20 20
Zinc (zinc sulfate), mg 11 30 30
Copper (encapsulated copper sulfate), mg 1.0 4 4
Calcium (tricalcium phosphate), mg 1000 0 280
Phosphorus (tricalcium phosphate), mg 700 0 190
Potassium (potassium chloride), mg 2900∗ 0 200
Magnesium (magnesium citrate), mg 350 0 65
Selenium (sodium selenite 1.5%), μg 60 130 130
Iodine (potassium iodate), μg 220 250 250
Manganese (manganese sulfate), mg 2.0∗ 2.6 2.6
1IFA capsule is standard of care and follows the WHO and Ghana Health Service recommendation; LNS for pregnant and lactating
women (24–29); MMN supplement capsule (30). ∗Adequate intake. IFA, iron and folic acid; LNS, lipid-based nutrient supplement;
MMN, multiple micronutrients; RE, retinol equivalents.
BP monitors (Andon BPM model KD-595). We collected a blood
sample by venipuncture and measured hemoglobin (Hb; Hemocue
AG), malaria parasitemia (Clearview Malarial Combo, Vision Biotech),
and the inflammatory markers C-reactive protein (CRP; mg/L) and
α1-acid glycoprotein (AGP; g/L) (Cobas Integra 400 plus Automatic
Analyzer, Roche Diagnostic Corp.) from plasma. Gestational age
estimates were determined at enrollment by physicians at the antenatal
clinics using ultrasound imagers (EDAN DUS 3 Digital Ultrasonic
Diagnostic Imaging System, EDAN Instruments, Inc.). Fieldworkers
distributed a 2-wk supply of the assigned supplement along with
instructions on consumption methods. Fieldworkers collected data on
supplement adherence, calculated as the percentage of pregnancy days
after enrollment that women reported consuming the supplement,
and morbidity at biweekly follow-up visits at the participants’
homes.
Fieldworkers visited the home or hospital at delivery to complete
anthropometric measurements of newborns. Birth weight was measured
to the nearest 20 g (Seca 383; Seca), and length (Seca 416; Seca) and head
circumference (Shorr Productions) to the nearest 0.1 cm. Measurements
were recorded within 48 h of birth for 91% of infants and between
3 and 14 d after birth for 9% of infants. For age- and sex-
standardization of weight, we used the WHO Child Growth Standards
(31). If the infant was measured >48 h after delivery, adjustments for
weight, length, and head circumference were calculated as previously
described (23).
Outcomes and definitions
The primary outcome for this secondary analysis of the effect of
the intervention was mean maternal SBP at 36 weeks of gestation.
We also examined mean DBP at 36 weeks of gestation, and risk
of high SBP or high DBP at 36 weeks of gestation by supplement
group. We defined hypertension as high SBP (≥130 mm Hg) or
high DBP (≥80 mm Hg) (1). To examine the association between
maternal BP and birth outcomes, our primary outcome was newborn
birth weight. Additional outcomes included newborn birth length,
head circumference, pregnancy duration, LBW (<2500 g), PTB
(<37 wk), stunting (length-for-age z score <−2), and SGA (birth
weight <10th percentile according to the Intergrowth Standards) (32).
PTB was examined only with respect to measurements of BP taken at
enrollment because many PTBs occurred before the BP measurements
at 36 weeks of gestation.
Statistical analysis
Effect of daily nutrient supplementation on maternal
hypertension.
For continuous outcomes, the difference between the 3 group means was
tested with ANOVA and ANCOVA models. If the null hypothesis was
rejected at the 0.05 significance level, post hoc pairwise comparisons
across the 3 intervention groups were conducted using the Tukey–
Kramer test for ANOVA to adjust for multiple comparisons. Log-
binomial models were used to estimate risk ratios (RRs) (33). If a
model did not converge, a log-Poisson model was used (33). Normality
for all variables was assessed using a Shapiro–Wilk statistic. At
enrollment, prepregnancy BMI, CRP, and AGP were not normally
distributed and were logarithmically transformed for analysis. The
heteroscedasticity assumption was examined through the plots and we
observed relatively equal variances. No outliers were identified through
visual inspection of the histograms or scatterplots. For each outcome,
we evaluated possible covariates to control for confounding by
16 prespecified variables: maternal (age, height, BMI, completed years
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681 not eligible  
224 lives outside study area 
203 HIV positive 
96 >20 wk gestation 
67 asthma 
56 planning move 
9 unwilling to receive visitors 
7 misdiagnosed pregnancy 
4 participating in a clinical trial 
4 age <18 
3 chronic respiratory disease 
2 peanut allergy  
2 epilepsy 
2 loss of pregnancy  
1 unwilling to take study 
supplement  
1 redundant (enrollment ended) 
 
255 not enrolled 
120 >20 wk of gestation after 
ultrasound 
77 >20 wk before completion of 
enrollment  
12 husband refused 
11 woman refused 
9 loss of pregnancy  
9 misdiagnosed pregnancy 
8 acute illness 
5 redundant (enrollment ended) 
1 in-law refused 
1 moved away 
1 planning to move away 
1 mental illness 
351 not recruited 
108 plan to move  
95 refused 
55 not found 
45 lives outside study area 
20 >20 wk of gestation 
13 husband refused 
9 loss of pregnancy  
4 unwilling to take supplement  
2 sickness 
Screened 
n = 2607 
Eligible 
n = 1926 
Recruited 
n = 1575 
Enrolled 
n = 1320 
IFA 
n = 441 
MMN 
n = 439 
LNS 
n = 440 
92 women excluded1 85 women excluded1 86 women excluded1 
Birth outcomes 
n = 349 
Birth outcomes 
n = 354 
Birth outcomes 
n = 354 
FIGURE 1 Study profile. The IFA group received 60 mg iron plus 400 mg folic acid. The MMN group received 1–2 Recommended Dietary
Allowances of 18 vitamins and minerals (including 20 mg iron). The LNS group received LNS with the same micronutrients as the MMN group,
plus another 4 minerals (Ca, P, K, and Mg), as well as macronutrients. All 3 supplements were intended for daily consumption. 1During the
study, IFA and MMN capsules were unintentionally mislabeled, causing 92 participants in the IFA group and 85 participants in the MMN group
to receive the incorrect supplement. A total of 86 women not-exposed in the LNS group, as well as the mixed-exposure women in the IFA or
MMN groups were excluded.
of education, marital status, parity, gestational age, season, treatment
group, Hb status, CRP, AGP, and malaria status), child (sex), and
household (socioeconomic status indicators—namely, assets and food
insecurity). Covariates that were statistically significantly associated
with the outcome (P < 0.1 in univariate models) were included in an
adjusted regression model. Among all the variables included in the final
adjusted model, there was no evidence of collinearity [variance inflation
factors (VIFs) <10] and all variables significantly associated with the
outcome were included in adjusted models. Owing to randomization
of the trial in the intervention, we followed the intention-to-treat
principle when analyzing the effect of LNSs on maternal BP. During
the study, some of the IFA and MMN capsules were unintentionally
mislabeled, causing 92 IFA women and 85 MMN women to have
mixed exposure during pregnancy. All women pregnant during the
period of mixed exposure were excluded from this analysis including
the 92 IFA and 85 MMN women who experienced mixed exposure,
as well as 86 LNS women. After exclusion the final sample size was
1057 (23). A sensitivity analysis including all participants (n = 1320)
was also conducted. Considering the protocol violation resulting in
mixed exposure, the analyses included intervention groups according
to the supplement treatment assignment actually received when they
were enrolled and not the treatment originally assigned at enrollment,
which is consistent with a previous iLiNS-DYAD publication reporting
birth size (23). All tests were 2-sided and conducted at a 0.05 level of
significance.
Association between maternal hypertension and birth
outcomes.
A prospective cohort study design was used to analyze the associations
between maternal BP (at enrollment and 36 weeks of gestation)
and birth outcomes. Multiple linear regression models were used to
determine the associations of SBP and DBP with birth weight, length,
head circumference, and duration of gestation. We checked all models
for linearity using quadratic terms and found a lack of any U-shaped
relations. Results of the regression models are presented as standardized
regression coefficients (β-coefficients), which allow for standardized
comparisons between the predictors and the outcome variables. Using
β-coefficients, a 1-SD increase in the predictor determines the change
in SDs of the outcome variable, with all other variables held constant.
Interactions between maternal BMI and BP, with respect to birth
outcomes, were assessed in linear regression and P values < 0.05 were
considered to be statistically significant. Log-binomial models were used
to estimate RR, 95% CIs, and P values for categorical birth outcomes in
adjusted and unadjusted models using both the old and new definitions
of high SBP, high DBP, and hypertension (33). In a few instances, the
models did not converge and log-Poisson models were used (33). The
categorical birth outcomes included LBW, SGA, PTB, and stunting. If the
null hypothesis was rejected at the 0.05 level, the Benjamini–Hochberg
procedure was used to compare P values to an adjusted significance
level that accounted for multiple tests related to birth outcomes (34).
Inclusion of covariates was used and tested as aforementioned. Both
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TABLE 2 Characteristics of pregnant Ghanaian women
enrolled between 2009 and 2011 in the International Lipid-Based
Nutrient Supplements-DYAD nutrient supplementation trial, by
supplement group1
Characteristic IFA MMN LNS
n 349 354 354
Maternal age, y 26.5 ± 5 26.9 ± 6 26.5 ± 5
Gestational age, wk 16.3 ± 3 16.2 ± 3 16.2 ± 3
Parous, % 62 69 64
BMI, kg/m2 24.5 ± 4 24.4 ± 4 24.7 ± 4
Height, cm 158.5 ± 6 159.1 ± 6 159.0 ± 5
Education, completed years 7.6 ± 4 7.5 ± 4 7.7 ± 4
Married or cohabitating, % 92 94 93
Offspring sex female, % 49 51 49
Plasma CRP, mg/L 3.8 (3.3, 4.3) 3.1 (2.8, 3.5) 3.3 (2.9, 3.8)
Plasma AGP, g/L 0.6 (0.6, 0.7) 0.6 (0.6, 0.6) 0.6 (0.6, 0.6)
Positive malaria test, % 9 8 11
SBP, mm Hg 112 ± 10 111 ± 12 112 ± 11
DBP, mm Hg 63 ± 7 64 ± 8 64 ± 8
High SBP, % 5 8 7
High DBP, % 3 3 5
HTN, % 7 9 8
1n = 1057. Values presented are mean ± SD or geometric mean (95% CI) unless
otherwise indicated. IFA capsule is standard practice and follows the WHO and
Ghana Health Service recommendation; LNS for pregnant and lactating women
(24–29); MMN supplement capsule (30). AGP, α1-acid glycoprotein; CRP, C-reactive
protein; DBP, diastolic blood pressure; HTN, hypertension; IFA, iron and folic acid;
LNS, lipid-based nutrient supplement; MMN, multiple micronutrients; SBP, systolic
blood pressure.
CRP and AGP were included as potential covariates owing to the
association between increased maternal inflammation and decreased
newborn birth size (35).
SAS software 9.4 (SAS Institute, Cary, NC) was used for data
analysis in addition to Microsoft Office Excel for the configuration of
figures.
TABLE 3 Unadjusted mean SBP and DBP at 36 weeks of
gestation in pregnant Ghanaian women enrolled between 2009
and 2011 in the International Lipid-Based Nutrient
Supplements-DYAD randomized trial of daily nutrient
supplementation in a semiurban setting, by intervention group1
IFA MMN LNS P value
n 349 354 354
SBP, mm Hg
Unadjusted 110 ± 10 110 ± 11 110 ± 11 0.704
Adjusted2 110 ± 10 110 ± 11 110 ± 11 0.958
DBP, mm Hg
Unadjusted 63 ± 7 62 ± 8 63 ± 8 0.266
Adjusted2 63 ± 7 62 ± 8 63 ± 8 0.668
1n = 1057. Values are mean ± SD. IFA capsule is standard practice and follows the
WHO and Ghana Health Service recommendation; LNS for pregnant and lactating
women (24–29); MMN supplement capsule (30). DBP, diastolic blood pressure; IFA,
iron and folic acid; LNS, lipid-based nutrient supplement; MMN, multiple
micronutrients; SBP, systolic blood pressure.
2The adjusted models presented the same means as the unadjusted models.
Confounding variables that had a statistically significant association with the
outcome (P < 0.1) were included in an adjusted regression model. Adjusted models
included prepregnancy BMI, gestational age, maternal age, completed years of
education, asset index, food insecurity index, hemoglobin status, maternal height,
plasma C-reactive protein, plasma α1-acid glycoprotein, parity, and malaria status; all
covariates were ascertained at study enrollment.
Results
Between December 2009 and March 2011, a total of 1320
pregnant women were enrolled in the main iLiNS-DYAD trial,
with a final sample size of 1057 for this analysis after excluding
women who were pregnant during the mixed-exposure period
(Figure 1). Only 4.4% of women dropped out of the study
before delivery and the attrition rate did not significantly
differ (P > 0.05) between the IFA (4.6%), MMN (3.7%),
and LNS (5.1%) groups (23). Table 2 shows maternal char-
acteristics at enrollment, by intervention group. At enrollment,
8.1% of women had hypertension (SBP ≥130 mm Hg or
DBP ≥80 mm Hg) with 6.6% of women having high SBP
and 3.6% having high DBP. At 36 weeks of gestation, 5.3%
of women had hypertension with 4.3% having high SBP and
2.4% having high DBP. Supplemental Table 1 presents the
characteristics of the total sample of women, as well as those
with normal BP and with hypertension at enrollment. Women
with hypertension were older on average and had greater
prepregnancy BMI and height than those without hypertension
(P < 0.05).
Supplement group comparisons
Table 3 shows that the unadjusted and adjusted means of SBP
and DBP at 36 weeks of gestation were not significantly different
between intervention groups. There were no statistically
significant differences in risk of maternal hypertension between
the intervention groups (Table 4). In the sensitivity analysis
including all 1320 pregnant women, neither SBP nor DBP
differed significantly by supplementation group in unadjusted
or adjusted analysis (data not shown).
Maternal BP and birth outcomes
BP as a continuous variable and birth outcomes.
Higher DBP at enrollment was associated with lower birth
weight (β: −0.087; 95% CI: −0.15, −0.020; P < 0.05)
and shorter pregnancy duration (β: −0.069; 95% CI: −0.14,
−0.0001; P = 0.05) in adjusted models (Supplemental Table 2).
For each 1-SD increase in DBP at enrollment (8 mm Hg),
birth weight was reduced by 0.087 SD, which translates to
37 g reduced birth weight per 1-SD increase in DBP. For each
1-SD increase in DBP at enrollment, duration of gestation was
reduced by 0.069 SD, which translates to an ∼1-d reduction
in gestation duration per 1-SD increase in DBP. When the
model for birth weight was further adjusted for duration
of gestation, the effect size was attenuated and no longer
statistically significant (β: −0.057; 95% CI: −0.117, 0.003;
P > 0.05).
Higher DBP at 36 weeks of gestation was associated with
a lower birth weight (β: −0.095; 95% CI: −0.16, −0.027;
P < 0.05) and length (β: −0.076; 95% CI: −0.14, −0.009;
P < 0.05) in adjusted models. For each 1-SD increase in DBP
at 36 weeks of gestation (8 mm Hg), birth weight was reduced
by 0.095 SD, which translates to 41 g reduced birth weight
per 1-SD increase in DBP. When the model for birth weight
was further adjusted for duration of gestation, the effect size
remained significant (β: −0.067; 95% CI: −0.13, −0.006; P
< 0.05). Higher SBP at 36 weeks of gestation was associated
with a lower birth weight (β: −0.074; 95% CI: −0.14, −0.008;
P < 0.05), birth length (β: −0.077; 95% CI: −0.14, −0.011;
P < 0.05), newborn head circumference (β: −0.072; 95% CI:
−0.14, −0.002; P < 0.05), and a shorter pregnancy duration
(β: −0.069; 95% CI: −0.14, −0.001; P < 0.05). When the
model for birth weight was further adjusted for duration of
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TABLE 4 Risk of high SBP or DBP at 36 weeks of gestation in pregnant Ghanaian women enrolled
between 2009 and 2011 in the International Lipid-Based Nutrient Supplements-DYAD randomized
trial of daily nutrient supplementation in a semiurban setting, between intervention groups1
IFA MMN LNS RR1 (95% CI) RR (95% CI)
n 349 354 354
High SBP, n (%) 12 (3.4) 14 (4.0) 19 (5.4)
Unadjusted 1.56 (0.77, 3.17) 1.36 (0.69, 2.66)
Adjusted2 1.37 (0.64, 2.92) 1.21 (0.61, 2.41)
High DBP, n (%) 6 (1.7) 8 (2.3) 11 (3.1)
Unadjusted 1.81 (0.68, 4.83) 1.38 (0.56, 3.38)
Adjusted2 1.91 (0.89, 4.08) 1.10 (0.39, 3.06)
1n = 1057. RR of high SBP (≥130 mm Hg) compared with normal SBP (<130 mm Hg), and high DBP (≥80 mm Hg) compared with
normal DBP (<80 mm Hg). IFA capsule is standard practice and follows the WHO and Ghana Health Service recommendation; LNS
for pregnant and lactating women (24–29); MMN supplement capsule (30). DBP, diastolic blood pressure; IFA, iron and folic acid;
LNS, lipid-based nutrient supplement; MMN, multiple micronutrients; RR, risk ratio; SBP, systolic blood pressure.
2Covariates that were significantly associated with the outcome (P < 0.1) were included in an adjusted regression model. Adjusted
models included prepregnancy BMI, gestational age, maternal age, completed years of education, asset index, food insecurity
index, hemoglobin status, maternal height, plasma C-reactive protein, plasma α1-acid glycoprotein, parity, and malaria status (for
MMN comparison); all covariates were ascertained at study enrollment.
gestation, the effect size was attenuated and no longer significant
(β: −0.043; 95% CI: −0.10, −0.017; P > 0.05).
High BP, using the new cutoffs, and birth outcomes.
Women with high DBP at enrollment had greater risk of
LBW (adjusted RR: 2.58; 95% CI: 1.09, 6.08) and PTB (RR:
3.30; 95% CI: 1.47, 7.40) than women with normal DBP
at enrollment (Table 5). Neither high SBP nor hypertension
at enrollment were significantly associated with LBW in
unadjusted or adjusted models (Table 5). Women with high
DBP at 36 weeks of gestation had greater risk of LBW (RR:
3.39; 95% CI: 1.32, 8.69); however, neither high SBP nor
hypertension at 36 weeks of gestation were associated with any
birth outcomes.
We observed variation in coefficients between unadjusted
and adjusted models and examined which covariates had the
greatest impact on results. BMI had a large influence in adjusted
models. At enrollment, higher BMI was associated with higher
SBP (β: 0.389; 95% CI: 0.330, 0.446; P < 0.05) and DBP
(β: 0.375; 95% CI: 0.320, 0.432; P < 0.05). Higher BMI at
enrollment was also associated with higher SBP (β: 0.401; 95%
CI: 0.350, 0.457; P < 0.05) and DBP (β: 0.394; 95% CI:
0.340, 0.450; P < 0.05) at 36 weeks of gestation, and newborn
birth weight (β: 0.266; 95% CI: 0.200, 0.328; P < 0.05). We
also checked all models for collinearity and confirmed all VIFs
were <2.
High BP, using previous cutoffs, and birth outcomes.
When using the prior BP cutoff, women with high DBP
(≥90 mm Hg) at enrollment had greater risk of LBW (RR:
8.50; 95% CI: 3.52, 20.57) and PTB (RR: 10.8; 95% CI: 4.87,
20.89) than women with normal DBP at enrollment. High SBP
(≥140 mm Hg) at enrollment was not significantly associated
with LBW in unadjusted or adjusted models (Supplemental
Table 3). Women with high DBP at 36 weeks of gestation had
greater risk of LBW (RR: 8.50; 95% CI: 3.52, 20.57); however,
neither high SBP nor hypertension were associated with any
birth outcomes.
Discussion
In this study, we determined that provision of LNS did not
have a significant effect on maternal BP during pregnancy, as
compared with provision of IFA or MMN. We also examined
associations between maternal BP and birth outcomes and
found that higher DBP and higher SBP were both associated
with lower birth weight and length and shorter pregnancy
duration. However, only high DBP (≥80 mm Hg) was associated
with increased risk of LBW and PTB, whereas high SBP,
according to the new cutoff of ≥130 mm Hg, was not associated
with risk of any adverse birth outcomes examined in this study.
Our findings that LNSs did not have a significant effect
on maternal BP are consistent with a previous trial conducted
in Bangladesh, which compared pregnant women consuming
either LNSs or IFA and found no significant difference in mean
SBP, DBP, or risk of hypertension (36). As was the case in
our population, the Bangladesh study sample also had a low
prevalence of hypertension as compared with the previously
reported country prevalence. However, both studies excluded
populations with chronic conditions, which may have led to
a lower prevalence of hypertension. Women in this Ghanaian
study population have been shown to have low urinary iodine
(37), but adequate plasma fatty acid levels (38) and low
prevalence of iron deficiency anemia (39). It is possible that
LNSs would show an effect on maternal BP in populations with
a higher prevalence of micronutrient deficiencies. The only other
study to date that has examined the effects of LNSs on BP was
a follow-up study of the children from our trial in Ghana which
reported no effect of prenatal and early childhood LNSs on child
BP at 4–6 y of age (40).
The associations we found in our study between BP and birth
outcomes are also consistent with previous research. A 2014
systematic review/meta-analysis of 55 studies confirmed an as-
sociation between hypertension and risk of LBW and PTB (14).
Our findings show that when using the previous definition the
association between hypertension at 36 weeks of gestation and
LBW (RR: 3.8) is similar in magnitude to the estimate from the
2014 systematic review/meta-analysis (RR: 2.7) that included
7 different definitions of hypertension during pregnancy.
Maternal hypertension may lead to reduced placental
perfusion, placental dysfunction, and/or increased inflammation
(9, 41), which could explain the association we observed
between hypertension and LBW. Inflammation may lead to fetal
hypoxia, which may inhibit fetal growth and thereby reduce
newborn birth weight (42). Alternatively, maternal hypertension
may actually be a consequence of fetal growth restriction,
because fetal growth restriction and placental dysfunction
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TABLE 5 Risk of adverse birth outcomes predicted by maternal BP at enrollment and 36 weeks of gestation in pregnant Ghanaian
women enrolled between 2009 and 2011 in the International Lipid-Based Nutrient Supplements-DYAD nutrient supplementation trial1
Low birth weight2 Small for gestational age3 PTB4 Stunting5
RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI) P
n (%) 93 of 931 (10) 189 of 897 (21) 76 of 931 (8) 81 of 925 (9)
Enrollment
Normal SBP, n 88 of 987 180 of 987 70 of 987 78 of 987
High SBP, n 5 of 70 9 of 70 6 of 70 3 of 70
Unadjusted 0.81 (0.34, 1.92) 0.633 0.71 (0.38, 1.31) 0.276 1.22 (0.55, 2.70) 0.619 0.54 (0.18, 1.68) 0.289
Adjusted 1.02 (0.38, 2.76) 0.969 0.90 (0.47, 1.72) 0.761 1.29 (0.55, 3.03) 0.566 0.50 (0.13, 1.97) 0.321
Normal DBP, n 88 of 1019 180 of 1019 70 of 1019 80 of 1019
High DBP, n 5 of 38 9 of 38 6 of 38 1 of 38
Unadjusted 1.55 (0.67, 3.55) 0.304 1.31 (0.74, 2.32) 0.356 2.33 (1.09, 4.98) 0.029∗ 0.34 (0.05, 2.35) 0.273
Adjusted 2.58 (1.09, 6.08) 0.031∗ 1.72 (0.95, 3.10) 0.074 3.30 (1.47, 7.40) 0.004∗ 0.51 (0.07, 3.71) 0.503
Normal BP, n 86 of 971 176 of 971 67 of 971 78 of 971
HTN, n 7 of 86 13 of 86 9 of 86 3 of 86
Unadjusted 0.97 (0.47, 2.02) 0.937 0.87 (0.53, 1.45) 0.599 1.60 (0.83, 3.08) 0.157 0.46 (0.15, 1.41) 0.172
Adjusted 1.27 (0.56, 2.90) 0.563 1.01 (0.59, 1.75) 0.958 1.89 (0.92, 3.86) 0.083 0.40 (0.10, 1.61) 0.198
36 weeks of gestation
Normal SBP, n 89 of 1012 180 of 1012 — 79 of 1012
High SBP, n 4 of 45 9 of 45 — 2 of 45
Unadjusted 1.03 (0.40, 2.66) 0.955 1.13 (0.63, 2.03) 0.682 — — 0.58 (0.15, 2.25) 0.428
Adjusted 2.01 (0.77, 5.26) 0.156 1.67 (0.91, 3.06) 0.099 — — 0.97 (0.25, 3.78) 0.966
Normal DBP, n 89/1032 184/1032 80/1032
High DBP, n 4 of 25 5 of 25 — 1 of 25
Unadjusted 2.05 (0.83, 5.03) 0.118 1.19 (0.55, 2.57) 0.655 — — 0.57 (0.08, 3.86) 0.561
Adjusted 3.39 (1.32, 8.69) 0.011∗ 1.54 (0.74, 3.20) 0.250 — — 0.86 (0.12, 6.24) 0.880
Normal BP, n 88 of 1001 179 of 1001 — 79 of 1001
HTN, n 5 of 56 10 of 56 — 2 of 56
Unadjusted 1.09 (0.47, 2.56) 0.838 1.06 (0.60, 1.86) 0.845 — — 0.48 (0.12, 1.91) 0.300
Adjusted 2.07 (0.85, 5.04) 0.108 1.45 (0.81, 2.62) 0.212 — — 0.77 (0.19, 3.05) 0.705
1RR of high SBP (≥130 mm Hg) compared with normal SBP (<130 mm Hg), high DBP (≥80 mm Hg) compared with normal DBP (<80 mm Hg), and HTN (high SBP or high
DBP) compared with normal BP. All covariates were ascertained at study enrollment. ∗Adjusted P value is statistically significant with Benjamini–Hochberg correction, P < 0.05.
Critical values are as follows: unadjusted PTB at enrollment, 0.116; adjusted PTB at enrollment, 0.016; adjusted LBW at enrollment, 0.062; adjusted LBW at 36 weeks of
gestation, 0.033. BP, blood pressure; DBP, diastolic blood pressure; HTN, hypertension; LBW, low birth weight; PTB, preterm birth; RR, risk ratio; SBP, systolic blood pressure;
SGA, small for gestational age.
2Adjusted SBP and DBP models for LBW included prepregnancy BMI, maternal age, asset index, food insecurity index, parity, offspring sex, and maternal height.
3Adjusted SBP models for SGA included prepregnancy BMI, maternal age, completed school years, parity, maternal height, log plasma C-reactive protein, and malaria status.
Adjusted DBP models for SGA included the same variables as SBP as well as log plasma α1-acid glycoprotein.
4PTB is defined as delivery before 37 weeks of gestation. PTB was examined only with respect to measurements of BP taken at enrollment because many PTBs occurred
before the BP measurements at 36 weeks of gestation. Adjusted SBP models for PTB included prepregnancy BMI, gestational age at enrollment, asset index, food insecurity
index, season at enrollment being dry season, malaria status, and treatment group. Adjusted DBP models for PTB included prepregnancy BMI, gestational age at enrollment,
asset index, food insecurity index, and season at enrollment being dry season.
5Adjusted SBP and DBP models for stunting included prepregnancy BMI, maternal age, asset index, food insecurity index, parity, season at enrollment being dry season, and
maternal height.
may decrease placental vasodilators, which are increasingly
important during late-pregnancy BP maintenance (43). The
exact underlying mechanisms for how maternal BP and birth
weight are related remain unclear.
Interestingly, although both SBP and DBP were associated
with lower birth weight, the magnitude of the association was
noticeably greater for DBP. A study by Bakker et al. (13) also
reported a greater magnitude of association for DBP and birth
weight than for SBP in a large cohort study of pregnant women
in the Netherlands. The functional differences between DBP and
SBP may explain our finding. The heart muscles relax and the
chambers fill with blood during diastole and contract to pump
blood into the arteries during systole. Vascular restructuring oc-
curs during pregnancy to increase blood flow and accommodate
the needs of the fetus for growth and development. Less filling
of the heart with blood will occur with higher DBP, which may
result in decreased cardiac output and blood flow to the placenta
for fetal growth and development (44).
The associations between DBP (at enrollment and
36 weeks of gestation) and birth weight were attenuated
with an adjustment for duration of gestation, which suggests
that duration of gestation may be a mediating factor in
the relation between DBP and birth weight. However, the
association between DBP at 36 weeks of gestation and birth
weight was significant even after adjusting for duration of
gestation.
Our findings show a positive relation between maternal
BMI and birth weight, and also a positive relation between
maternal BMI and BP. These associations may explain the
substantial impact that maternal BMI has on adjusted results.
This suggests that there are opposing pathways with regard
to how maternal BMI might influence birth size. Higher BMI
may lead to greater newborn birth size, but if the mother
also develops high BP, that may counter the effect of higher
BMI, because high BP is associated with a smaller birth
size.
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Strengths of our study include the large prospective design
with BP measurements in early and late pregnancy, a low
loss to follow-up, the use of ultrasound scans to determine
gestational age, and the use of the most recent cutoff definitions
for hypertension. A limitation of our study was that adherence
to supplement consumption was based primarily on participant
self-report. However, fieldworkers also visited the houses
biweekly and counted any unconsumed supplements to assist
in confirming adherence. In addition, participants were able
to distinguish between small-quantity LNS sachets and IFA or
MMN capsules. However, anthropometrists and data analysts
were blinded to group assignments. It should be noted that
maternal BP was not the main outcome of the iLiNS trial and
it is possible that the quality of the BP measurements could
have been improved. Either the left or right arm was used to
take BP measurements, and it is possible that the duplicate
measurements were not appropriately timed, i.e., they may
have been taken within 5 min of each other. We did not have
information related to the use of antihypertensive medications
during pregnancy; however, it is likely that only a limited
number of women, if any, were using such medications during
pregnancy given the low prevalence of hypertension in this
study. Lastly, the low prevalence of hypertension may introduce
bias and may be due to the exclusion of women with chronic
conditions, as previously mentioned. Future studies should
further explore the etiology of maternal hypertension and
associations with birth outcomes using the updated BP cutoffs.
Within a sample of Ghanaian women, this analysis examined
the impact of prenatal supplementation on maternal hyper-
tension risk using the new, more conservative hypertension
threshold. We did not observe differential effects of daily
prenatal LNS, MMN, or IFA supplementation on maternal
hypertension risk. Thus, although LNS is shown to benefit
maternal and newborn health in this population (37–39), our
results do not support its use to prevent maternal hypertension.
Independently of the supplement intervention, however, we
found that higher BP was associated with lower birth weight,
length, and head circumference and shorter pregnancy duration,
and maternal hypertension was associated with an increased
risk of LBW and PTB. This suggests that the updated diagnostic
threshold for hypertension may be a useful criterion for
identifying women at greater risk of adverse birth outcomes,
and that efforts to address hypertension during pregnancy to
improve birth outcomes are needed.
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